라미부딘 내성 만성 B형 간염 환자에서 라미부딘과 아데포비어 병용치료 = Lamivudine and adefovir combination therapy in patients with Lamivudine-resistant HBeAg-positive chronic hepatitis B

다국어 초록 (Multilingual Abstract)

Background/Aims: This study assessed the clinical efficacy of lamivudine-adefovir combination therapy and adefovir monotherapy for 96 weeks in patients who had hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) with genotypic resistance to lamivudine. Methods: We reviewed 134 patients who had HBeAg-positive CHB with genotypic resistance to lamivudine. We assessed liver function tests, hepatitis B virus (HBV) DNA, HBeAg, and antibody every 12 weeks after adefovir treatment. We searched for adefovir-related mutations in patients with biochemical or virologic breakthrough after adefovir treatment. Results: Data on 34 patients receiving combination therapy and 100 patients receiving monotherapy were analyzed. After 96 weeks, 82.4% of the combination therapy and 69.0% of the monotherapy patients had normalized alanine aminotransferase (ALT) levels (p=0.132). In addition, 50.0% and 37.0% achieved undetectable HBV DNA (p=0.210), respectively, and 23.5% and 20.0% lost HBeAg (p=0.662). The combination therapy group (5.9%) showed significantly lower biochemical breakthrough than the monotherapy group (22.0%, p=0.034) and had a lower cumulative biochemical breakthrough rate (p=0.043). One patient (2.9%) receiving combination therapy and 11 patients (11.0%) receiving monotherapy developed genotypic resistance to adefovir (p=0.155). One rtA181V mutation was detected in the combination therapy group, and ten rtA181V mutations and one rtN236T mutation were detected in the monotherapy group. Conclusions: Combination therapy had higher rates of ALT normalization, undetectable HBV DNA, and HBeAg loss and a lower rate of adefovir resistance. Monotherapy had significantly higher biochemical breakthrough and cumulative biochemical breakthrough rates than combination therapy. Therefore, combination therapy was clinically more effective than monotherapy. (Korean J Med 77:716-722, 2009)

참고문헌 (Reference)

1 Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B" 44 : 283-290, 2006

2 Benhamou Y, "Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine- resistant hepatitis B virus: an open-label pilot study" 358 : 718-723, 2001

3 Papatheodoridis GV, "Review article: current management of chronic hepatitis B" 19 : 25-37, 2004

4 Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil" 55 : 1488-1495, 2006

5 Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B" 36 : 687-696, 2003

6 Liaw YF, "No benefit to continue lamivudine therapy after emergence of YMDD mutations" 9 : 257-262, 2004

7 Conjeevaram HS, "Management of chronic hepatitis B" 38 : S90-S103, 2003

8 Yatsuji H, "Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two year follow- up" 48 : 923-931, 2008

9 Lampertico P, "Low resistance to adefovir combined with lam ivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients" 133 : 1445-1451, 2007

10 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

11 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

12 Santantonio T, "Long-term follow-up of patients with anti-HBe/HBV DNA positive chronic hepatitis B treated for 12 months with lamivudine" 32 : 300-306, 2000

13 Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States" 341 : 1256-1263, 1999

14 Chin R, "In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2’-fluoro-5-methyl-beta-L-arabinofuranosyluracil" 45 : 2495-2501, 2001

15 Fung SK, "Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?" 40 : 790-792, 2004

16 Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy" 33 : 1527-1532, 2001

17 Hadziyannis SJ, "Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B" 32 : 847-851, 2000

18 Liaw YF, "Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group" 119 : 172-180, 2000

19 Papatheodoridis GV, "Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease" 36 : 219-226, 2002

20 Chen CH, "Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants" 41 : 454-461, 2004

21 Di Marco V, "Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine" 40 : 883-891, 2004

22 Lok AS, "Chronic hepatitis B: update of recommendations" 39 : 857-861, 2004

23 Fung J, "Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population" 12 : 41-46, 2007

24 Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B" 348 : 808-816, 2003